NCT02509052View on ClinicalTrials.gov

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

September 18, 2018

Study Completion Date

June 9, 2022

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leflunomide

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02509052 - Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter